Drug Database
DI

diphtheria + tetanus + pertussis + hepatitis-B vaccine

✓ Approved

Microgen · 疫苗 · 疫苗

什么是 diphtheria + tetanus + pertussis + hepatitis-B vaccine?

diphtheria + tetanus + pertussis + hepatitis-B vaccine 是一种疫苗,由Microgen研发。该药已获批,用于治疗相关适应症。

药物档案

公司Microgen
药物类别疫苗
状态Approved

治疗适应症

diphtheria + tetanus + pertussis + hepatitis-B vaccine 针对 4 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Infections and infestationsDiphtheria✓ Approved
Infections and infestationsHepatitis B✓ Approved
Infections and infestationsPertussis✓ Approved
Infections and infestationsTetanus✓ Approved

相关研究文献

PubMedInfection and immunity2026-11-17

Co-administration of DTaP with COVID-19 mRNA vaccine in mice alters immune responses and induces increased protection from Bordetella pertussis challenge.

Rader Nathaniel N, Boehm Dylan T DT, Bitzer Graham J GJ, Chapman Joshua J et al.

During the COVID-19 pandemic, children received COVID-19 mRNA vaccines alongside other regularly scheduled immunizations, such as the acellular Bordetella pertussis vaccine DTaP. It is known that mRNA vaccines are pro-inflammatory in nature, leading to protective immunity against SARS-CoV-2 infection. The goal of this study was to investigate the potential adjuvanticity of co-administration of a COVID-19 mRNA vaccine alongside DTaP. Mice were immunized with DTaP alone or with a co-administration of DTaP plus COVID-19 mRNA vaccine. To understand the impact of co-administration, we evaluated protection against B. pertussis aerosol challenge in mice and potential correlates of protection, including cytokine responses to vaccination, antibody responses, and single-cell transcriptomic analysis of the draining lymph node. Three decreasing doses of each vaccine were used to simulate waning immunity. Overall, compared to mice immunized with DTaP, co-administration of DTaP + COVID-19 mRNA vaccines elicited higher pro-inflammatory cytokine responses, higher IgG2b antibody responses, and mice were afforded increased protection against aerosol challenge of B. pertussis. Single-cell transcriptomics studies on the lymph node of vaccinated mice at 1 day post-boost further characterized how co-administration of COVID-19 mRNA vaccine alongside DTaP vaccine shapes immunity. Single-cell transcriptomics revealed that co-administration of DTaP and COVID-19 mRNA vaccine generated populations of B and T cells with upregulated expression of interferon-stimulated genes, which were absent when vaccinating with DTaP alone. Altogether, these data suggest that administering DTaP alongside COVID-19 mRNA vaccine alters immune responses and provides increased protection from an aerosol challenge of B. pertussis compared to DTaP alone in mice.

PMID 43043313
阅读全文 →
PubMedBMC infectious diseases2026-11-17

Clinical characteristics and indicators associated with poor in-hospital prognosis among children with severe pertussis in Shandong Province, China (2022-2024).

Wang Ping P, Li Jian J

Pertussis is a life-threatening respiratory infection among young infants. This retrospective study enrolled only children already diagnosed with severe pertussis. We aimed to describe clinical characteristics and identify indicators associated with poor in‑hospital prognosis within this severe cohort, rather than exploring predictors for progression from mild to severe pertussis. A retrospective observational study was conducted among 80 children diagnosed with severe pertussis who were hospitalized between January 2022 and December 2024. Clinical data, laboratory results, treatment, and outcomes were collected. Multivariate logistic regression and receiver operating characteristic (ROC) curve analysis were applied to screen indicators associated with composite poor in-hospital prognosis and evaluate their prognostic performance.Composite poor in-hospital prognosis was defined as new in-hospital adverse events including invasive mechanical ventilation, pertussis encephalopathy with persistent neurological sequelae, or all-cause in-hospital death; 6 out of 80 participants met this composite endpoint. White blood cell count was included as a continuous variable in multivariate regression. The optimal cutoff of > 30 × 10⁹/L was derived from ROC analysis for descriptive and potential bedside reference only and was not used for regression modelling. The median age was 4 months and 19 days (range, 1 month 14 days to 5 years); 65.0% (52/80) of patients were infants ≤ 3 months who could not receive routine diphtheria, pertussis, and tetanus (DPT) vaccine. All patients presented paroxysmal cough, and 95% had inspiratory whoop. Leukocytosis (WBC > 20 × 10⁹/L) was observed in 45.0% of children; 75.0% had patent foramen ovale (PFO), and 18.80% developed secondary cardiac abnormalities. Erythromycin combination therapy carried a significantly higher risk of liver dysfunction than monotherapy (36.40% vs. 8.60%, P < 0.05). Multivariate logistic regression identified three independent correlates of composite poor prognosis: unvaccinated status (OR = 4.2, 95%CI 1.8-9.6, P = 0.001), mixed bacterial-viral co-infection (OR = 3.5, 95%CI 1.2-10.1, P = 0.023), and elevated continuous white blood cell count (OR = 5.1, 95%CI 2.3-11.4, P < 0.001). Given the limited number of poor-prognosis events (n = 6), these adjusted associations should be interpreted cautiously as exploratory findings.ROC analysis using continuous WBC count yielded an AUC of 0.678, whereas the combined prognostic model derived from multivariable logistic regression achieved an AUC of 0.689. Infants aged ≤ 3 months constituted the majority of children hospitalized with severe pertussis. After adjusting for age-related vaccination eligibility, unvaccinated status, mixed bacterial-viral co-infection, and higher white blood cell count were independently associated with poor in-hospital prognosis. ROC analysis demonstrated only modest discriminative performance of these indicators; at present, they serve merely as potential references and require external validation before any clinical application. Not applicable.

PMID 43040268
阅读全文 →
PubMedGeriatrie et psychologie neuropsychiatrie du vieillissement2026-11-17

[2026 vaccination schedule for adults aged 65 years and older: towards comprehensive vaccine-based prevention in older age].

Corroyer-Simovic Bénédicte B

The 2026 French vaccination schedule redefines geriatric prevention, extending its focus beyond the prevention of infectious diseases to the preservation of independence and functional health. Yet vaccination coverage in France remains inadequate. To address immunosenescence, the strategy prioritizes comprehensive protection against respiratory infections caused by influenza viruses, SARS-CoV-2, pneumococcus and respiratory syncytial virus (RSV). For influenza, guidelines recommend the preferential use of enhanced vaccines-either high-dose or adjuvanted formulations-to improve protection in older adults and reduce hospital admissions. Covid-19 boosters remain essential for this vulnerable population, with the adjuvanted recombinant protein vaccine Nuvaxovid® available alongside mRNA vaccines. Pneumococcal prevention is considerably simplified: a single dose of the 21-valent pneumococcal conjugate vaccine (PCV21, Capvaxive®) is recommended for all adults aged 65 years and older. This vaccine covers the serotypes responsible for 83.5% of invasive pneumococcal disease cases in France in 2024. RSV vaccination is indicated for adults aged 75 years and older and for those aged 65 years and older with cardiopulmonary comorbidities, providing protection against severe disease and reducing hospital admissions during winter. Beyond respiratory infections, vaccination against herpes zoster with the adjuvanted recombinant vaccine Shingrix® is recommended for all adults aged 65 years and older. Recent data associate this vaccination not only with the prevention of postherpetic neuralgia but also with a reduced risk of stroke. Tdap-IPV boosters remain essential in the context of recent pertussis epidemics and the persistent risk of tetanus in older adults. Vaccine coadministration is safe and should be offered to improve coverage and reduce the number of visits required. When vaccination records are unavailable, the priority is to proceed with vaccination rather than delay protection. This proactive, integrated approach aims to address inadequate vaccination coverage, reduce mortality and preserve independence in older adults.

PMID 43042679
阅读全文 →
PubMedJournal of clinical immunology2026-11-17

SIMPATHY Study: Specific Antibody Response to Typhim Vi Polysaccharide as a Surrogate Marker of Infectious Risk in Secondary Immunodeficiency Associated with B Cell Cancer.

Peixoto-Rodriguez Alejandro A, Melero Josefa J, de Andrés Ana A, López-Granados Eduardo E et al.

Recurrent and severe infections represent a major cause of morbidity and mortality of secondary immunodeficiency (SID) associated with B-cell lymphoproliferative syndromes (B-CLPD). Nevertheless, immunological evaluation and prophylactic interventions are often delayed until infectious complications occur. Early vaccination is therefore relevant not only because it provides protection during the initial phases of B-CLPD, but also because it enables the identification of patients at higher risk of infection. In this context, assessment of antigen-specific humoral response has been proposed as a useful biomarker for identifying patients with greater clinical vulnerability. We conducted SIMPATHY (Secondary Immunodeficiency Multicentric study on the Antibody Production to Typhi vaccine), a multicentre, retrospective, observational study including 128 individuals with B-CLPD, classified according to the presence or absence of severe and/or recurrent infections, as well as healthy controls. Specific IgG antibody responses to Streptococcus pneumoniae (13-valent conjugate, Prevenar), Salmonella typhi (Typhim Vi), and tetanus toxoid vaccines were assessed at baseline and 4-weeks after vaccination. Among 128 individuals analysed, patients with B-CLPD showed significant immunological and clinical differences compared to healthy controls, particularly in vaccine-specific antibody responses and lymphocyte subsets. B-CLPD patients with recurrent or severe infections exhibited markedly reduced pre-vaccination anti-pneumococcal (p = 0.03) and post-vaccination anti-pneumococcal (p = 0.001) and anti-Salmonella typhi Vi titers (p = 0.1), highlighting impaired vaccine-specific antibody responses as potential predictors of infection risk. An immunological classification identified two subgroups within B-CLPD, predominant antibody defect and combined immune defect, with a trend toward higher respiratory infection rates in the latter, suggesting broader immune dysfunction.

PMID 43040101
阅读全文 →
PubMedHepatology forum2026-11-17

Reverse hepatitis B seroconversion without immunosuppression: A case report and literature review.

Zhu Kai K, Wu Eric E, Tam Benson B, Yoshida Eric M EM et al.

We report a case of reverse hepatitis B seroconversion in an 88-year-old woman with previously resolved hepatitis B virus (HBV) infection and sustained virologic response to hepatitis C virus (HCV) therapy. She presented with decompensated cirrhosis and was found to have newly positive hepatitis B surface antigen, hepatitis B e-antigen, and high HBV DNA levels, despite no recent immunosuppression. Entecavir was initiated with clinical and virologic improvement. This case highlights the potential for HBV reactivation years after apparent clearance, even in the absence of immunosuppression, and underscores the need for long-term monitoring in patients with prior HBV infection.

PMID 43042239
阅读全文 →
PubMedBMC gastroenterology2026-11-17

Incidence of liver cancer and decompensated cirrhosis amongst hepatitis B and C notifications in Tasmania- a data linkage study.

Ibegu Maria M, Le Tuan Nguyen Anh A, Stephens Nicola N, de Graaff Barbara B

Liver cancer is a leading cause of cancer-related death globally, with both incidence and mortality rates rising sharply in Australia over the past three decades. Chronic hepatitis B and C are major contributors to liver cancer, and its common precursor, decompensated cirrhosis. This study assessed the incidence of liver cancer and decompensated cirrhosis among individuals with hepatitis B and C in Tasmania. A retrospective population-based study was conducted using linked datasets. The cohort included all individuals with a notification for hepatitis B and/or C in Tasmania from 1995 to 2022. Cases were linked to the Tasmanian Cancer Register and admitted patient data from Tasmanian public hospitals. Incidence rates per 1,000 person-years were calculated for liver cancer and decompensated cirrhosis. Between 1995 and 2022, 1,280 hepatitis B (55.5% male) and 6,658 hepatitis C (64.3% male) notifications were recorded in Tasmania. A total of 145 liver cancer registrations and 270 decompensated cirrhosis-related admissions were observed. Among individuals with hepatitis B, the incidence rates were 5.39 per 1,000 person-years for liver cancer and 3.00 per 1,000 person-years for decompensated cirrhosis. Among those with hepatitis C, corresponding rates were 2.33 and 5.02 per 1,000 person-years. While the number of liver-related outcomes was relatively low and did not support more detailed analyses, a trend towards higher incidence rates was observed over the study period. These findings highlight the burden of liver-related complications among individuals with hepatitis B and C in Tasmania. Liver cancer was more common among those with hepatitis B, while decompensated cirrhosis was more frequent among those with hepatitis C. Observed trends should be interpreted cautiously, as they may reflect changes in population characteristics, surveillance, and healthcare engagement. Strengthening testing, treatment uptake, and long-term monitoring is essential to reduce the burden of advanced liver disease in this regional setting.

PMID 43040487
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多diphtheria + tetanus + pertussis + hepatitis-B vaccine